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ORIGINAL ARTICLEHyperpolarized 129Xenon Magnetic Resonance Imaging
to Quantify Regional Ventilation Differences in
Mild to Moderate Asthma
A Prospective Comparison Between Semiautomated Ventilation Defect
Percentage Calculation and Pulmonary Function TestsLukas Ebner, MD,* Mu He, MS,†‡ Rohan S. Virgincar, MS,† Timothy Heacock, MD,§
Suryanarayanan S. Kaushik, PhD,k Matthew S. Freemann, PhD,†¶ H. Page McAdams, MD,*
Monica Kraft, MD,§ and Bastiaan Driehuys, PhD*†k¶Objectives: The aim of this study was to investigate ventilation in mild to mod-
erate asthmatic patients and age-matched controls using hyperpolarized (HP)
129Xenonmagnetic resonance imaging (MRI) and correlate findings with pulmo-
nary function tests (PFTs).
Materials andMethods: This single-center, Health Insurance Portability and
Accountability Act–compliant prospective study was approved by our insti-
tutional review board. Thirty subjects (10 young asthmatic patients,
26 ± 6 years; 3 males, 7 females; 10 older asthmatic patients, 64 ± 6 years;
3 males, 7 females; 10 healthy controls) were enrolled. After repeated PFTs
1 week apart, the subjects underwent 2 MRI scans within 10 minutes, inhal-
ing 1-L volumes containing 0.5 to 1 L of 129Xe. 129Xe ventilation signal was
quantified by linear binning, from which the ventilation defect percentage
(VDP) was derived. Differences in VDP among subgroups and variability
with age were evaluated using 1-tailed t tests. Correlation of VDP with PFTs
was tested using Pearson correlation coefficient. Reproducibility of VDP was
assessed using Bland-Altman plots, linear regression (R2), intraclass correlation
coefficient, and concordance correlation coefficient.
Results:Ventilation defect percentage was significantly higher in young asth-
matic patients versus young healthy subjects (8.4% ± 3.2% vs 5.6% ± 1.7%,
P = 0.031), but not in older asthmatic patients versus age-matched controls
(16.8% ± 10.3% vs 11.6% ± 6.6%, P = 0.13). Ventilation defect percentage
was found to increase significantly with age (healthy, P = 0.05; asthmatic pa-
tients, P = 0.033). Ventilation defect percentage was highly reproducible
(R2 = 0.976; intraclass correlation coefficient, 0.977; concordance correlation co-
efficient, 0.976) and significantly correlated with FEV1% (r = −0.42, P = 0.025),Received for publication April 29, 2016; and accepted for publication, after revision,
July 5, 2016.
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Copyright © 2016 Wolters Kluwer HFEF25%–75% (r = −0.45, P = 0.019), FEV1/FVC (r = −0.71, P < 0.0001), FeNO
(r = 0.69, P < 0.0001), and RV/TLC (r = 0.51, P = 0.0067). Bland-Altman anal-
ysis showed a bias for VDP of −0.88 ± 1.52 (FEV1%, −0.33 ± 7.18).
Conclusions: 129XenonMRI is able to depict airway obstructions inmild tomod-
erate asthma and significantly correlates with PFTs.
Key Words: lung MRI, hyperpolarized xenon gas, airway obstruction, asthma,
pulmonary function tests
(Invest Radiol 2017;52: 120–127)
A sthma has a prevalence of 6% to 8% in the American populationthat peaks in early childhood, declines in late adolescence, and
rises again in the late adulthood before decreasing among the elderly.1,2
While the diagnosis and clinical monitoring of asthma mainly
use forced expiratory volume in 1 second (FEV1%), these pulmonary
function tests (PFTs) do not completely characterize airway physiology.
Even in subjects with normal FEV1%, nitrogen washout shows that sig-
nificant ventilation heterogeneity can be present.3 Similarly, computed
tomography (CT) can reveal heterogeneous regional air-trapping and
airway thickening in asthmatic patients4 with normal PFT results. The
most striking shortcoming of PFTs is their broad variation with age,
standing height, sex, and ethnic group.5,6 These observations support
the need for more precise and reliable measurements that do not require
such scaling. In addition to being highly variable, PFTs also cannot de-
pict regional ventilation or its heterogeneity. Ventilation defects could
represent preclinical stages of disease, offering the opportunity of better
monitoring disease progress or treatment efficiency. Another possible
application could include early detection of disease-related ventilation
defects to further avoid exacerbations.7
To this end, xenon-enhanced dual-energy CT has been able to
depict regional ventilation but confers a considerable radiation dose,
which particularly limits the use in healthy subjects and young individ-
uals.8 Therefore, MRI techniques are emerging that use short echo time
sequences in conjunction with oxygen shortening lung tissue T1 to pro-
vide a surrogate of regional ventilation.9 Although the oxygen enhance-
ment signal depends on more than regional ventilation, it has been
shown to significantly correlate with PFT measurements. However,
oxygen-enhanced MRI is hampered by relatively small signal, long ac-
quisition times, and the need for subtraction that can make it prone to
misregistration artifacts.10
Even more advantageous are nonproton MR methods that di-
rectly image nonendogenous inhaled agents, such as perfluorinated
gases, without background signal.11 However, the most thoroughly in-
vestigated and mature nonproton method over the last 2 decades has
been hyperpolarized (HP) 3He MRI.12–15 This technique also readily
depicts ventilation heterogeneity and defects and has been used to visu-
alize the effects of both bronchoprovocation and bronchodilation.16 The
observed ventilation defects on HP 3He MRI significantly correlatedInvestigative Radiology • Volume 52, Number 2, February 2017
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tered on CT.17 3He MRI has shown that older asthmatic patients exhibit
significantly more ventilation defects than younger ones.11 Unfortu-
nately, 3He gas is in short supply and faces sharply rising costs, which
has increased interest in readily available HP 129Xe. This gas has al-
ready been shown to detect more ventilation defects in asthmatic pa-
tients than 3He.18 However, there are no studies further investigating
obstructive patterns in asthma with 129Xe MRI or correlating this tech-
niquewith PFTs. This gap must be addressed in order for 129XeMRI to
expand into clinical practice.
The purpose of our study was to investigate if 129Xe MRI would
(a) correlate significantly with established lung function metrics; (b) ac-
curately depict differences in ventilation defect percentage (VDP) be-
tween asthmatic patients and healthy controls; and (c) be reproducible
at baseline.
MATERIALS AND METHODS
This prospective, single-center Health Insurance Portability and
Accountability Act–compliant study was approved by the institutional
review board and registered at clinicaltrials.gov. All subjects gave in-
formed, written consent before study enrollment.
Patients
Between January 2012 and March 2014, 30 subjects were pro-
spectively recruited for this study (20 asthmatic patients, 10 age-
matched healthy controls). Both study populations were matched for
sex, asthma medication use, and percent predicted forced expiratoryFIGURE 1. Flowchart of study recruitment and the diagnostic
workup timeline.
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Hvolume (FEV1%). Asthma was confirmed with a methacholine chal-
lenge test according to American Thoracic Society guidelines.6 The
population was further stratified by age to young (18-35 years; n = 9)
and older (55–75 years; n = 10) asthmatic patients, and included 5
age-matched healthy subjects for each age group.
The following exclusion criteria were applied: (1) smoking his-
tory of more than 5 pack-years or smoked for the past 2 years;
(2) prebronchodilator FEV1% < 60%; (3) diffusing capacity of the lung
for carbon monoxide (DLCO) < 80% predicted; (4) asthma exacerba-
tion requiring oral corticosteroids or respiratory tract infection in the
past 6 weeks; (5) had been hospitalized for respiratory disease in the
past 3 months; and (6) were asthmatic and using more than short-
acting β-agonist and/or inhaled corticosteroids (dose equivalent of
≤250 mg fluticasone). General contraindications for MRI also resulted
in exclusion from the study.
All individuals participated in 3 separate visits on different days
at the same time of the day within ±2 hours (Fig. 1). On the first visit,
clinical characteristics were recorded and a physical examination was
performed. During this session, DLCO and fractional exhaled nitric
oxide (FeNO) were measured, and the Asthma Quality of Life Question-
naire (AQLQ), as well as the Asthma Control Questionnaire (ACQ), was
administered.19 At the second visit (1 week ± 3 days later), subjects re-
turned to the clinic and repeated spirometry, DLCO, AQLQ, FeNO,
and sequential sputum induction to more accurately measure these pa-
rameters (learning/training effect). At the third and final visit, 129Xe ven-
tilation MRI was performed.
Pulmonary Function Testing
Spirometry, plethysmography, and DLCOwere performed using
the Vmax Autobox and SensorMedics (CareFusion, San Diego, CA).
Spirometry was used to measure FEV1, FEF25%–75%, and FVC, whereas
plethysmography was used to assess lung volumes (total lung capacity
[TLC], residual volume [RV]). Ratios such as FEV1/FVC and RV/TLC
were calculated from raw data, but all values are reported as percentage
of the predicted values for subjects of comparable characteristics. Frac-
tional exhaled nitric oxide, indicating airway inflammation, was mea-
sured using the Niox Mino (Aerocrine Inc USA, Morrisville, NC).
Asthmatic patients were classified according to the guidelines of the
US National Asthma Education and Prevention Program.
Magnetic Resonance Imaging
Hyperpolarized 129Xe MRI scans were performed on a 1.5 T
GE Healthcare EXCITE 15M4 MR system. Isotopically enriched 129Xe
gas (83% 129Xe) was polarized to 6% to 10% by spin-exchange optical
pumping.20 Subjects underwent 2 fast gradient echo 129Xe ventilation
MRI scans in the supine position, 10 minutes apart, using 1 L of total
gas volume, composed of 0.5 to 1 L of HP 129Xe, mixed with N2 buffer
gas as described previously.21 In all cases, the subject received a total
volume of gas of 1 L. The xenon volume was determined by the dura-
tion of cryogenic accumulation and total gas flow rate. As 129Xe polar-
ization levels became higher, smaller predetermined 129Xe volumes
could be used. In case this volume was less than 1 L, helium buffer
gas was added to make 1 L.
From each 129Xe MRI scan, VDP was calculated using the
linear-binning approach.22 Subjects were fitted with a flexible chest coil
(Clinical MR Solutions, Brookfield, WI) that was tuned to a 17.66-
MHz 129Xe frequency and proton-blocked to permit anatomical scans
to be acquired using the 1H body coil. After being positioned on the
scanner bed, subjects first inhaled a test dose of room air to learn the
breathing maneuver. 1H images were acquired in a separate breath hold
before the 129Xe scan. For the 1H scans, subjects inhaled 1 L of air from
the gas bag to achieve a similar level of lung inflation. Individuals were
coached to inhale 129Xe from functional residual capacity. A first bag of
gas mixture was used to calibrate the scanner transmit/receive settingswww.investigativeradiology.com 121
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TABLE 1. Sequence Parameters for Thoracic Cavity Registration and the HP 129Xe Ventilation Image
Parameter
Thoracic Cavity 1H Image
Steady-State Free Precession Sequence
HP 129Xe Ventilation Image
Spoiled Gradient Echo Sequence
Repetition time, ms 2.8 7.9
Echo time, ms 1.2 1.9
Flip angle, degrees 45 5–7
Slice thickness, mm 12.5 12.5
Field of view, cm2 40  40 40  28–40
Acquisition matrix 128  128 128  90–128
Receiver bandwidth, kHz 125 8
Acquisition time, s 15 10–14
Ebner et al Investigative Radiology • Volume 52, Number 2, February 2017in each imaging session. Subjects then underwent 2 HP 129Xe ventila-
tion MRI scans, 10 minutes apart, containing 1 L of total gas volume,
composed of 0.5 to 1 L of HP 129Xe, mixed with N2 buffer gas. The
2 xenon doses were administered to the patient in the supine position.
Specific sequence parameters are summarized in Table 1.
Image Analysis
Images were quantified to determine their VDP using a corrected,
semiautomated linear-binning approach, first described by He et al.22
The analysis of the Xe signal was confined to a mask generated by
segmenting the proton images to delineate the thoracic cavity. Before
segmentation, these images had been registered to the HP 129Xe venti-
lation MRI scans. Both registration and segmentation by region grow-
ing used Avizo (Visualization Sciences Group, Burlington, MA). The
HP 129Xe images were then corrected for transmit/receive inhomogene-
ity and rescaled by the 99th percentile of their cumulative intensity dis-
tribution, such that all intensities ranged from 0 to 1. This permitted
each 129Xe voxel within the thoracic cavity to be classified into 1 of 4
clusters (<0.2, defect; 0.2–0.4, low intensity; 0.4–0.8, medium inten-
sity; and >0.8, high intensity). The volume of the lowest-intensity clus-
ter (<0.2) relative to that of the thoracic cavity was used to quantifyFIGURE 2. Example of false ventilation defects caused by artifacts. A, In this h
scan. Ventilation defect percentage clusters less than 0.2 (red)were slightly visib
attributed to rib cage impressions (white arrows) representing artifacts. These
resegmentation. B, Young asthmatic subject with FEV1% = 80%, which had t
binning algorithm (C) to overestimate VDP at 22.4%. Figure 2 can be viewed
122 www.investigativeradiology.com
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the lungs were color-coded on the ventilation maps: red indicates de-
fect; yellow, low intensity; green, medium intensity; and blue, high sig-
nal intensity. Before statistical analysis, the HP 129Xe ventilation
images and the corresponding color-coded maps were reviewed in con-
sensus by 2 readers (blinded to the review process, with 6 and 10 years
of experience in chest imaging) to verify that image quality was suit-
able. Image quality was determined to be inadequate for further analysis
if the images exhibited extensive coil shading or insufficient signal to
noise to undergo binning analysis.
Statistical Analysis
Statistical analysis was performed using JMP 12 (SAS Insti-
tute Inc, Cary, NC) and MedCalc 16.1 (MedCalc Software, Ostend,
Belgium). Ventilation defect percentage and its change with age were
compared between healthy subjects and asthmatic patients using
1-tailed tests; these were justified based on prior knowledge that VDP
increases with asthma and age.23 Correlation between VDP and PFTs
was evaluated using the Pearson correlation coefficient (r). Reproduc-
ibility of VDP over the 2 consecutive scans was assessed using linear
regression, intraclass correlation coefficient, concordance correlationealthy young volunteer, VDP was 7.28% at baseline and 8.33% at second
le at baseline and becomemore severe at rescan. These defects could be
artifacts were identified during the review and were resolved by manual
o be excluded because of extensive coil shading, which caused the
online in color at www.investigativeradiology.com.
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TABLE 2. Summary of the Subject Demographics, Results of the PFTs, and the VDP
YH (n = 5) YA (n = 9) OH (n = 5) OA (n = 10)
Subject demographics
Age (±SD), y 23.2 (±1.3) 25.9 (±6.4) 63.4 (±5.8) 63.2 (±6.1)
Male/female 2/3 2/7 2/3 3/7
BMI, kg/m2 23.7 (±2.5) 29.0 (±8.2) 29.0 (±5.2) 30.3 (±4.1)
ACQ N/A 1.3 (±0.9) N/A 1.7 (±1.2)
AQLQ N/A 6.1 (±0.8) N/A 5.0 (±1.9)
PFTs
FEV1% 106 (±14.5) 84 (±16.1) 95.8 (±14.3) 81.1 (±19.8)
FVC% 111.4 (±12.8) 98.8 (±16.2) 104.0 (±18.1) 96.4 (±12.7)
FEV1/FVC 81.0 (±8.2) 72.2 (±7.1) 71.7 (±11.2) 64.5 (±11.2)
FEF25%–75% 96.2 (±32.3) 59.2 (±21.9) 87.3 (±35.5) 53.1 (±26.9)
RV/TLC 0.18 (±0.02) 0.29 (±0.12) 0.31 (±0.05) 0.40 (±0.05)
DLCO mmol CO 86.8 (±10.5) 97.1 (±10.8) 89.5 (±10.8) 98.4 (±17.3)
FeNO ppb 16.8 (±8.1) 33.8 (±21.4) 15.6 (±10.2) 36.9 (±48.2)
Eos sputum % 4.0 (±5.0) 5.1 (±7.2) 9.3 (±3.4) 5.5 (±3.8)
HP 129Xe MRI
VDP 5.6 (±1.8) 8.7 (±3.2) 11.6 (±6.6) 16.8 (±10.3)
All values are averages of measurements over 2 time points and are reported as mean ± standard deviation for the cohort.
PFT indicates pulmonary function test; VDP, ventilation defect percentage; YH, young healthy; YA, young asthmatic; OH, old healthy; OA, old asthmatic; BMI,
body mass index; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FEV1%, forced expiratory volume in 1 second; FVC%, forced
vital capacity; FEF, forced mid-expiratory flow rate; RV/TLC, residual volume/total lung capacity; DLCO, diffusing capacity of the lung for carbon monoxide; FeNO,
fractional exhaled nitric oxide; HP, hyperpolarized; MRI, magnetic resonance imaging; N/A, not applicable.
Investigative Radiology • Volume 52, Number 2, February 2017 Xe MRI for Ventilation Assessment in Asthmacoefficient,21 as well as by Bland-Altman analysis. Results were con-
sidered statistically significant with P < 0.05.
RESULTS
Patients
A total of 30 subjects were enrolled and completed the entire
study protocol, with no serious adverse events reported during the im-
aging sessions. Mild adverse effects related to xenon inhalation (tin-
gling, euphoria, dizziness) resolved within 3 minutes after exhalation.
No further adverse effects could be observed. One patient was excluded
because the MRI scans were corrupted by shading artifacts, determinedFIGURE 3. Left, Representative HP 129XeMRI ventilation scan in a healthy youn
hold is largely homogeneous. In the corresponding maps, faint red clusters ar
Right, 129Xe MRI of an older healthy volunteer with FEV1% = 102%. Compare
periphery, leading to VDP = 14.4%. Figure 3 can be viewed online in color at
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Hto be caused by a malfunctioning coil (Fig. 2). This artifact could not be
corrected by retrospective bias field correction due to insufficient sig-
nal. This resulted in a final sample size of 29 subjects, of which 19 were
mild to moderate asthmatic patients. Pulmonary function test and VDP
results are displayed in Table 2.
HP 129Xe MRI Ventilation Defect Analysis
Among all the patients included in the final study cohort, healthy
young volunteers yielded the most uniform 129Xe distribution (VDP,
5.6% ± 1.7%; Fig. 3). By comparison, young asthmatic patients exhib-
ited significantly more ventilation defects (VDP, 8.4% ± 3.2%;
P = 0.031; Fig. 4). Similarly, older asthmatic patients also showed moreg volunteer with FEV1%= 124%. The 129Xe distribution during the breath
e primarily attributable to slight misregistration, yielding VDP = 3.83%.
d with the young normal, this subject exhibits modest defects in the lung
www.investigativeradiology.com.
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FIGURE 4. Left, Young asthmatic subject; FEV1%= 59%:Moderate ventilation defects are foundmainly in the lung periphery and are triangular in shape.
On corresponding binning maps, ventilation defects are seen in red, as well as some high signal intensity pixels (blue). VDP: 14.6%. Right, An older
asthmatic is depicted on the right; FEV1% = 53%. Scattered ventilation defects are visible throughout the whole lung parenchyma. Both upper and lower
lobes, as well as hilar and peripheral lung regions, are almost equally affected. The corresponding VDPmaps yielded a total VDP percentage of 44.2%.
Figure 4 can be viewed online in color at www.investigativeradiology.com.
Ebner et al Investigative Radiology • Volume 52, Number 2, February 2017defects than older healthy subjects (16.8% ± 10.3% vs 11.6% ± 6.6%;
Figs. 3, 4). However, this difference was not significant (P = 0.13).
Older subjects generally exhibit higher VDP (Fig. 2), and this increase
with age was found to be statistically significant (healthy subjects,
P = 0.05; asthmatic patients, P = 0.02) (Table 3).
Comparison of VDP and PFTs
Correlation results are reported in Table 4. Ventilation defect
percentage showed a moderate correlation with FEV1% (r = −0.42,
P = 0.025), FEF25%–75% (r = −0.45, P = 0.019), and RV/TLC
(r = 0.51, P = 0.0067), and a strong correlation with FEV1/FVC
(r = −0.70, P < 0.0001; Fig. 5). In addition to PFTs, VDP also cor-
related strongly with the FeNO (r = 0.69, P < 0.0001). VentilationTABLE 3. Parameters
Healthy vs Asthma Young vs Old
Comparison Young Old Healthy Asthma
PFTs
FEV1% 0.014 0.065 0.15 0.36
FVC% 0.069 0.22 0.24 0.36
FEV1/FVC 0.041 0.20 0.14 0.045
FEF25%–75% 0.031 0.12 0.36 0.30
RV/TLC 0.014 0.042 0.020 0.018
DLCO mmol CO 0.060 0.16 0.37 0.42
FeNO ppb 0.036 0.10 0.42 0.57
Eos Sputum % 0.80 0.091 0.063 0.45
HP 129Xe MRI
Average VDP 0.031 0.13 0.05 0.016
The acquired parameters were tested for significant differences among the
healthy and asthma subjects, and also for change with age. Note: significant dif-
ferences are displayed in bold font-type.
PFT indicates pulmonary function test; FEV1%, forced expiratory volume in
1 second; FVC%, forced vital capacity; FEF, forced mid-expiratory flow rate;
RV/TLC, residual volume/total lung capacity; DLCO, diffusing capacity of the
lung for carbonmonoxide; FeNO, fractional exhaled nitric oxide;HP, hyperpolarized;
MRI, magnetic resonance imaging; VDP, ventilation defect percentage.
124 www.investigativeradiology.com
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ACQ, and the AQLQ questionnaires.
Repeatability of HP 129Xe VDP and PFTs
The repeatability of VDP proved to be excellent with an
intraclass correlation coefficient of 0.977 and concordance correlation
coefficient of 0.976 between the 2 MRI scans. Figure 6, A and B, addi-
tionally show the results of linear regression and Bland-Altman analysis
for VDP. Linear regression yielded an excellent least squares fit for
VDP with R2 = 0.976 (P < 0.0001). Bland-Altman analysis depicted a
small bias (±SD) in VDP of −0.88 ± 1.52, which is largely driven by
2 subjects who had a difference of ~4% between the 2 scans. In contrast,
the variability in FEV1% at 1 week was ±183 mL (7.18%) across the
subject population, which is well illustrated by the Bland-Altman plot
for FEV1% (Fig. 6D).DISCUSSION
Our study results show that the VDP derived from HP 129Xe
MRI is able to detect regional obstruction and significantly correlates
with PFTs.
Ventilation defect percentage was moderately to strongly corre-
lated with FEV1%, FEF25%–75%, FEV1/FVC, and RV/TLC. FEV1%
is the predominant metric used for quantitative assessment of airflow
limitation in asthma.24,25 Of note, VDP correlated significantly with
FEV1%, FEF25%–75%, FEV1/FVC, and RV/TLC. However, numerous
subjects with normal FEV1% exhibit pronounced ventilation defects,
and yet others with abnormal FEV1% exhibit almost normal lung ven-
tilation onMR. This speaks to the different ways these 2 techniques are
sensitive to obstruction. In order for HP 129Xe to be detectable in a
given voxel, the gas must travel largely unobstructed through all 23 gen-
erations of airways. This makes HP 129Xe MRI inherently sensitive to
the entire bronchial tree, whereas the measurement of FEV1% is known
to be dominated by contributions from the larger airways.26
HP 129Xe VDP further correlated with FEF25%–75% (r = −0.45,
P = 0.019), which is thought to be a more sensitive indicator of
small airways obstruction. This parameter reflects the most effort-
independent segment of the spirometric curve, dominated by flow in the
small airways. It is here that diseases of chronic airflow obstruction are
thought to start, and thus, the correlation of FEF25%–75% with HP
129Xe
VDP bolsters the notion that VDP is indeed sensitive to small airways ob-
struction. Because FEF25%–75% is known to be less reproducible than© 2016 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 4. Correlations of PFTs to VDP
Correlation With VDP r P
FEV1% −0.42 0.0249
FVC% −0.09 0.6284
FEV1/FVC −0.71 <0.0001
FEF25%–75% −0.45 0.019
RV/TLC 0.51 0.0067
DLCO mmol CO 0.34 0.0858
FeNO ppb 0.69 <0.0001
Eos Sputum% 0.00 0.9631
Note: significant results are displayed in boldface.
PFT indicates pulmonary function test; VDP, ventilation defect percentage;
FEV1%, forced expiratory volume in 1 second; FVC%, forced vital capacity;
FEF, forced mid-expiratory flow rate; RV/TLC, residual volume/total lung capac-
ity; DLCO, diffusing capacity of the lung for carbon monoxide; FeNO, fractional
exhaled nitric oxide.
Investigative Radiology • Volume 52, Number 2, February 2017 Xe MRI for Ventilation Assessment in AsthmaFEV1%,27HP 129XeMRImay provide amore reliablemetric of small air-
ways obstruction. A finding of potential clinical interest was the strong
correlation between VDP and FeNO (r = 0.69,P < 0.0001), which reflects
inflammatory activity and may thus aid in the distinction between young
asthmatic patients and young healthy subjects. The sputum eosinophilic
count was another recorded measure of airway inflammation; this mea-
sure did not correlate with VDP.
The comparison between HP 129Xe VDP and PFTs are relatively
virgin ground. To the best of our knowledge, there are only 2 compara-
ble publications addressing the correlations of HP 129Xe VDP and spi-
rometry. In a cohort of COPD subjects, Kirby and coworkers showed aFIGURE 5. Correlation of VDP and FEV1%, FEV25%-75%, FEV1/FVC, and RV/TL
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Hsignificant correlation between 3He and HP 129Xe MRI VDP, as well as
their correlation to FEV1% and FEV1/FVC. In addition, they found
that VDP derived from HP 129Xe MRI was significantly higher than
from 3He.28 Kirby and colleagues emphasized that the low density of
helium likely makes it less sensitive to obstruction than xenon. To date,
the sole study of HP 129XeMRI in an asthma population was conducted
by Svenningsen et al16 who focused primarily on bronchodilator re-
sponse and did not report on baseline correlations of HP 129Xe VDP
with PFTs.
One cannot overemphasize the need for reproducible markers of
airway obstruction. The high degree of variability of FEV1% is one of
the major reasons why respiratory clinical trials require large numbers
of patients to record an effect. By comparison, the high repeatability ob-
served with HP 129Xe MRI has the potential to mitigate the variability
impacting PFTs. We evaluated the repeatability of HP 129Xe MRI by
conducting short-term follow-up scans as previously reported with
3He MRI.29 In particular, the Bland-Altman analysis yielded only a
minimal variation of ±1.52%, whereas the variability of FEV1% was
found to be ±7.18%. Although the time between FEV1 measurements
was considerably longer than for HP 129XeMRI, such variability is con-
sistent with the known short-term variability of FEV1%.25,30
Our study results can have important clinical implications.
Measures of VDP with HP 129Xe MRI can be clinically leveraged
in monitoring asthma-related changes in ventilation in patients with
mild to moderate disease. Supported by the correlation with PFTs
and its remarkable repeatability, VDP derived from HP 129Xe MRI
could be valuable for the longitudinal assessment of disease progres-
sion and therapy response.
Ventilation defect percentage calculation from HP 129Xe MRI
is, however, not immune to physiologic states that can potentially
hinder the image interpretation. Notably, we observed a substantial
overlap in VDP values between old asthmatic patients and age-C.
www.investigativeradiology.com 125
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FIGURE 6. Linear regression and Bland-Altman plots for the 2 repeatedmeasures of VDP and FEV1%. Linear regression (A andC) showedhigh agreement
between the 2 scans for VDP (R2 = 0.976), and slightly lower for FEV1% (R2 = 0.879). Solid lines indicate the least squared fit. Bland-Altman analysis
(B and D) yielded a bias ± SD of −0.88 ± 1.52 for VDP, and −0.33 ± 7.18 for FEV1. Solid line indicates the mean difference and dotted lines indicate the
standard deviation about this mean.
Ebner et al Investigative Radiology • Volume 52, Number 2, February 2017matched controls. These subjects could be distinguished by using
RV/TLC, which is a marker of changes occurring in the aging lung
(ie, senile emphysema).31,32
Despite these promising results and possible applications, HP
noble gas MRI is not yet used in routine clinical practice. Although
the technology (particularly 3He) has been thoroughly studied for 2 de-
cades, it is still limited to selected academic institutions. This can be
partially attributed to the complex and nontraditional workflow of HP
agents, and the fact that it has not yet been approved by Food and Drug
Administration or similar authorities internationally.
Limitations
Our study had notable limitations. Along with the small sam-
ple size in the setting of a prospective case-control design, there were
differences in the time lapse between repeat measurements of PFTs
(ie, 1 week) and MRI (ie, 10 minutes). Thus, the high repeatability of
129Xe MRI observed on short time scales should, in the future, also
be verified at longer time scales. In our study, the proton scan and the
HP 129Xe ventilation scan were not acquired during the same breath
hold owed to the long scan time for each sequence. Consequently, the
alignment of the proton images and the ventilation images might not
be perfect, potentially leading to artifacts in the binning maps. Future
trials could benefit from implementing combined HP gas ventilation
images and proton images within a single breath hold.33 This approach
could facilitate the quantification of ventilation defects. Another limita-
tion is represented by the lack of widespread availability of HP noble
gasMRI, still to date confined to selected academic institutions. Finally,
one could argue that findings from HP 129Xe MRI would further126 www.investigativeradiology.com
Copyright © 2016 Wolters Kluwer Hbenefit from correlation with other imaging modalities (eg, conven-
tional CT imaging).
In conclusion, our data shows that HP 129Xe MRI is able to
quantify airway obstructions in mild to moderate asthma and signifi-
cantly correlates with PFTs. Its high reproducibility can make this tech-
nique a surrogate for PFTs in surveillance of ventilation impairment in
asthma patients.
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